Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130 ...

n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium Breast and Ovarian Analysis of Disease Incidence and ...

Platform can help predict a woman's 5-year risk for developing breast cancer by analyzing routine mammograms. HealthDay News — The US Food and Drug Administration has granted de novo authorization to ...

Improving infusion therapy management in metastatic breast cancer: Real-world pilot study of a new pharmacy resource. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

"We hope our findings will help women better understand their risk of developing the disease across the course of life, so that they can make informed, individualized decisions about screening and ...